Source: NICE
Area: News
In its Final Appraisal Determination (FAD), NICE does not support the use of fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies.
The Appraisal Committee concluded that, despite the manufacturer providing an updated economic model following consultation on the previous draft guidance, this model underestimated the incremental cost-effectiveness ratio (ICER) for the implant compared with optimised standard of care, resulting in an incremental cost effectiveness ratio (ICER) of £19,300 per QALY gained. The Committee concluded that the most plausible ICER was likely to be at least £47,600 per QALY gained and that the implant exceeded the range that NICE considers an effective use of NHS resources.
The Chief Executive of NICE said: "The independent Appraisal Committee is aware of the significant impact that chronic diabetic macular oedema can ...
Uncategorized